Loading patent…
AssigneeSuzhou Inhal Pharma Co., Ltd.
InventorsKaiqi Shi, Qingzhen Zhang, Fangyan Wang, Xunxun Liu, Riwei Yang, Xiujie Liu, Yingliang Ma, Jingxu Zhu
Estimating the term…
An inhalation formulation for treating an IPF disease. The inhalation formulation is an aerosol inhalation liquid formulation, an inhalation aerosol, a dry powder inhaler or a soft mist inhaler. The inhalation formulation contains an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole, and difamilast. A preparation process for the inhalation formulation is introduced into a conventional formulation. An active component in a conventional oral formulation is prone to being destroyed in the digestive tract, and has low bioavailability, a liver first pass effect, and a slow onset of action. An inhalation formulation capable of significantly alleviating IPF is prepared. Tests prove that the prepared inhalation formulation can effectively increase the bioavailability, and improve the clinical use effect.
A pharmaceutical formulation comprising an active drug selected from the group consisting of apremilast, ibudilast, crisaborole, and difamilast, wherein the pharmaceutical formulation is formulated as an inhalation formulation that increases bioactivity of the active drug for the treatment of an idiopathic pulmonary fibrosis (IPF) disease or condition by decreasing the level of malondialdehyde (MDA) or hydroxyproline (HYP) in lung.
Dependencies are inferred from the claim text.